

# National Board of Examinations

<b>Question Paper Name :</b>	DrNB CLINICAL HAEMATOLOGY Paper3
<b>Subject Name :</b>	DrNB CLINICAL HAEMATOLOGY Paper3
<b>Creation Date :</b>	2023-10-15 15:58:34
<b>Duration :</b>	180
<b>Share Answer Key With Delivery Engine :</b>	No
<b>Actual Answer Key :</b>	No

## DrNB CLINICAL HAEMATOLOGY Paper3

<b>Group Number :</b>	1
<b>Group Id :</b>	3271872629
<b>Group Maximum Duration :</b>	0
<b>Group Minimum Duration :</b>	180
<b>Show Attended Group? :</b>	No
<b>Edit Attended Group? :</b>	No
<b>Group Marks :</b>	100
<b>Is this Group for Examiner? :</b>	No
<b>Examiner permission :</b>	Cant View
<b>Show Progress Bar? :</b>	No

## DrNB CLINICAL HAEMATOLOGY Paper3

<b>Section Id :</b>	3271872632
<b>Section Number :</b>	1
<b>Section type :</b>	Offline

<b>Mandatory or Optional :</b>	Mandatory
<b>Number of Questions to be attempted :</b>	10
<b>Section Marks :</b>	100
<b>Enable Mark as Answered Mark for Review and Clear Response :</b>	Yes
<b>Maximum Instruction Time :</b>	0
<b>Sub-Section Number :</b>	1
<b>Sub-Section Id :</b>	3271872636
<b>Question Shuffling Allowed :</b>	No
<b>Is Section Default? :</b>	null

**Question Number : 1 Question Id : 32718726974 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

**Please write your answers in the answer booklet within the allotted pages as follows:-**

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Describe role of MRD assessment of prognosis in a patient with *de novo* AML. [3]
- b) Describe newer targeted treatment strategies in an adult patient with *de novo* AML. [4]
- c) Compare efficacy of myeloablative and non myeloablative matched sibling allogeneic stem cell transplantation in a patient with *de novo* AML. [3]

**Question Number : 2 Question Id : 32718726975 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe the prognostic markers of B chronic lymphocytic leukemia (CLL). [3]

- b) Describe the management strategy for a young patient (<40 years) with B - CLL. [4]
- c) Enumerate the newer therapeutic targets in B chronic lymphocytic leukemia. [3]

**Question Number : 3 Question Id : 32718726976 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe diagnostic and treatment approach to a female patient with menorrhagia and isolated prolonged aPTT. [6]
- b) Describe management strategies in a patient with acquired hemophilia A. [4]

**Question Number : 4 Question Id : 32718726977 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Enumerate the various treatment options of relapsed multiple myeloma post-autologous bone marrow transplantation. [6]
- b) Describe role of CAR-T cell therapy and its evidence in patients with relapsed and refractory multiple myeloma. [4]

**Question Number : 5 Question Id : 32718726978 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe role of factor prophylaxis in hemophilia A management and its challenges in Indian settings. [5]
- b) Describe the non-factor therapies in hemophilia. [2]
- c) Gene therapy in Hemophila: Where are we now?. [3]

**Question Number : 6 Question Id : 32718726979 Question Type : SUBJECTIVE Consider As**

**Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe principles behind next generation sequencing (NGS) technique. [3]
- b) Describe the role of NGS in management of AML. [3]
- c) Describe recent WHO classification of myeloid malignancies. [4]

**Question Number : 7 Question Id : 32718726980 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Enumerate various causes of concurrent thrombosis and thrombocytopenia. [3]
- b) Describe the pathophysiology of thrombotic thrombocytopenic purpura (TTP). [3]
- c) Describe management strategies that are evidence based in a patient with disseminated intravascular coagulation (DIC). [4]

**Question Number : 8 Question Id : 32718726981 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe various prognostic scoring systems for myelodysplastic syndromes. [6]
- b) Describe the management strategy for a low-risk MDS patient [4]

**Question Number : 9 Question Id : 32718726982 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

- a) Describe pathophysiology of SARS CoV 2 associated coagulopathy. [3]
- b) Describe the treatment approach of newly diagnosed AML presented with CoV 2 associated pneumonia. [4]
- c) Write a note on vaccine associated thrombosis and thrombocytopenia. [3]

**Question Number : 10 Question Id : 32718726983 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0**

**Correct Marks : 10**

a) Describe cutaneous manifestations of lymphoma. [5]

b) Describe diagnostic and therapeutic approach to a patient with Sezary syndrome. [5]